Literature DB >> 27770456

Control of asthma by omalizumab: the role of CD4+ Foxp3+ regulatory T cells.

F Amat1,2,3, P Tallon1, A P Foray4,5, B Michaud1,4, N Lambert1,3, P Saint-Pierre3,6, L Chatenoud4,5, J Just1,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27770456     DOI： 10.1111/cea.12839

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN： 0954-7894            Impact factor:   5.018


× No keyword cloud information.
  4 in total

1.  Regulation of IgE activity in inhalational tolerance via formation of IgG anti-IgE/IgE immune complexes.

Authors:  Sonali J Bracken; Alexander J Adami; Ektor Rafti; Craig M Schramm; Adam P Matson
Journal:  Clin Mol Allergy       Date:  2018-05-18

Review 2.  Two decades with omalizumab: what we still have to learn.

Authors:  Cristoforo Incorvaia; Marina Mauro; Elena Makri; Gualtiero Leo; Erminia Ridolo
Journal:  Biologics       Date:  2018-10-26

Review 3.  Advances and Challenges of Antibody Therapeutics for Severe Bronchial Asthma.

Authors:  Yuko Abe; Yasuhiko Suga; Kiyoharu Fukushima; Hayase Ohata; Takayuki Niitsu; Hiroshi Nabeshima; Yasuharu Nagahama; Hiroshi Kida; Atsushi Kumanogoh
Journal:  Int J Mol Sci       Date:  2021-12-22       Impact factor: 5.923

4.  Dawn of Monitoring Regulatory T Cells in (Pre-)clinical Studies: Their Relevance Is Slowly Recognised.

Authors:  A Charlotte M T de Wolf; Carla A Herberts; Marcel H N Hoefnagel
Journal:  Front Med (Lausanne)       Date:  2020-04-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.